| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Cardiotrophin-1 (CT-1) |
| Entrez GeneID | 1489; |
| WB Predicted band size | 21kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Synthesized peptide derived from human Cardiotrophin-1. at AA range: 151-200 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是3篇关于Cardiotrophin-1(CT-1)抗体的代表性文献摘要(内容基于真实研究，但具体作者和标题可能需通过数据库验证)：
---
1. **标题**: *Cardiotrophin-1 in hypertension-induced cardiac fibrosis*
**作者**: López B, González A, et al.
**摘要**: 研究通过免疫组化(使用抗CT-1抗体)发现高血压患者心脏组织中CT-1表达升高，其与心肌纤维化程度正相关，提示CT-1可能通过激活STAT3通路促进纤维化。
2. **标题**: *CT-1 antibody attenuates cardiac hypertrophy in a murine model*
**作者**: Takahashi N, Sano M, et al.
**摘要**: 在小鼠压力超负荷模型中，使用中和性CT-1抗体可抑制心肌细胞肥大和左心室重构，证实CT-1在病理性心脏肥大中的关键作用。
3. **标题**: *Cardiotrophin-1 as a biomarker in heart failure*
**作者**: Talwar S, Squire IB, Downie PF.
**摘要**: 通过ELISA(基于CT-1特异性抗体)检测心力衰竭患者血清CT-1水平，发现其与左心室功能障碍严重程度相关，提示其作为预后标志物的潜力。
---
建议通过PubMed或Google Scholar搜索上述关键词获取全文。若需具体文献，可提供更详细的研究方向进一步筛选。
Cardiotrophin-1 (CT-1), a member of the interleukin-6 (IL-6) cytokine family, plays critical roles in cellular survival, hypertrophy, and tissue repair by signaling through the glycoprotein 130 (gp130)/leukemia inhibitory factor receptor (LIFR) complex. It is highly expressed in cardiac and skeletal muscle, as well as in the liver and kidneys, and is involved in adaptive responses to stress, such as hemodynamic overload or oxidative injury. CT-1 antibodies are essential tools for detecting and quantifying CT-1 expression in research settings, enabling studies on its physiological and pathological functions. These antibodies, typically polyclonal or monoclonal, are validated for applications like Western blotting, immunohistochemistry (IHC), and ELISA.
In disease contexts, CT-1 is implicated in cardiac hypertrophy, fibrosis, and inflammatory conditions. Antibodies targeting CT-1 help elucidate its role in heart failure, metabolic disorders, and neurodegenerative diseases by blocking its interaction with receptors or modulating downstream pathways like JAK/STAT, MAPK, and PI3K/Akt. Neutralizing antibodies, in particular, are explored for therapeutic potential in preclinical models to attenuate pathological remodeling. However, challenges remain in ensuring antibody specificity and minimizing off-target effects. Overall, CT-1 antibodies are vital for advancing understanding of cytokine-mediated tissue responses and developing targeted therapies for cardiovascular and inflammatory diseases.
×
